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Abstract
Non-tuberculous mycobacteria are environmental, opportunistic pathogens that are increasingly being recognized as important causes of
many human diseases. Among them, rapidly growing mycobacteria are the most notorious organisms causing infectious keratitis. Non-
tuberculous mycobacterial (NTM) keratitis commonly occurs after trauma or refractive surgery, and can masquerade as fungal, herpetic or
amoebic keratitis. Therefore, the diagnosis is often delayed. Prolonged medical treatment and judicious surgical debridement are required in
order to eradicate the pathogens. Combination therapy with aminoglycosides, macrolides and ﬂuoroquinolones improves the prognosis and
decreases the occurrence of drug resistance. However, regardless of the development of new diagnostic techniques and antimicrobials,
NTM keratitis remains a clinical challenge for most ophthalmologists. In this article, we provide a concise introduction to the
epidemiological features and clinical characteristics of NTM keratitis, and the modern diagnostic tools used for it. We also summarize the
current concepts of prevention and treatment for this potentially devastating condition.
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Introduction
Since the ﬁrst report published by Turner in 1965 [1], non-
tuberculous mycobacteria have become increasingly recog-
nized as important causes of infectious keratitis [2–5].
Traditionally, non-tuberculous mycobacteria have been divided
into Runyon groups I–IV on the basis of colony characteristics
[6]. Runyon group IV, known as the rapidly growing myco-
bacteria (RGM), is the most noticeable group of human
keratitis pathogens [1,4,5,7]. Of all reported cases of non-
tuberculous mycobacterial (NTM) keratitis,83.5% are caused
by two subgroups of RGM, the Mycobacterium fortuitum group
and the Mycobacterium chelonae–abscessus group [5]; the other
16.5% of cases are caused by Runyon groups I–III, the slowly
growing mycobacteria (SGM) or non-tuberculous mycobacte-
ria of unknown species. The SGM, Mycobacterium szulgai,
Mycobacterium terrae, Mycobacterium gordonae, Mycobacterium
marinum, Mycobacterium avium–intracellulare, Mycobacterium
nonchromogenicum, Mycobacterium triviale and Mycobacterium
asiaticum have been reported to infect the human cornea [5].
Unlike for tuberculosis and leprosy, the environment is
considered to be the source of human NTM diseases.
Non-tuberculous mycobacteria are present in natural waters
and soils worldwide [8,9]. An important pathogenic property of
non-tuberculous mycobacteria is in their ability to develop
bioﬁlm. Bioﬁlm protects non-tuberculous mycobacteria from
disinfectants, and facilitates their attachment to the surface
interface. As a result, non-tuberculous mycobacteria can also
survive in artiﬁcial environments, such as daily water distribution
systems in operating theatres and swimming pools [10]. The
bioﬁlm then contributes to the opportunistic NTM infection.
We have reviewed the risk factors for the development of NTM
keratitis, the epidemiology, and the clinical presentation.
Current trends in diagnosis and treatment have also been
emphasized, followed by an analysis of general outcomes.
Risk factors
An important risk factor for the development of NTM keratitis
is trauma with penetration of the corneal epithelium [5]. The
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epithelium is the ﬁrst barrier for most pathogens. Therefore,
contact lens wearers who develop corneal abrasions appear to
be at risk of NTM infection [11]. Trauma, including that caused
by corneal foreign bodies [2], ocular surgery [12], and trivial
procedures such as suture removal [13], can all inoculate the
non-tuberculous mycobacteria into the deep corneal stroma.
Patients receiving topical steroids, such as corneal transplant
recipients, are also at risk [12]. Steroid use will suppress the
granulomatous inﬂammation and facilitate the growth of non-
tuberculous mycobacteria [14].
After the mid-1990s, with the advances in refractive surgery,
the number of cases of NTM keratitis after laser-assisted in situ
keratomileusis (LASIK) increased dramatically [4,5,7]. Out-
breaks of NTM keratitis after LASIK have been reported in
Brazil, the USA, and Japan. These outbreaks were related to
improper sterilization of surgical ﬂuid and instruments [15–17],
leading to the pathogens being introduced into the corneal
stroma during a surgical procedure.
Epidemiology
The overall incidence of infectious keratitis ranges between
0.0063% and 0.71%, with higher rates in developing countries
[18]. Regional variations in causative organisms do exist. The
data taken from two large referral centres have shown that
non-tuberculous mycobacteria are identiﬁed in only 1.1–7.9%
of all cases of infectious keratitis [3,19]. Although the overall
incidence of infectious keratitis after LASIK is still low, with an
incidence between 0.035% and 0.31% in recent reports [20],
non-tuberculous mycobacteria have been reported to be some
of the most common pathogens (47%) causing post-LASIK
keratitis [21].
The cases of NTM keratitis can be divided into two main
groups, i.e. post-LASIK and non-LASIK-related groups. The
age of patients developing NTM keratitis post-LASIK ranges
between 23 and 57 years, with a mean age of 37 years,
reﬂecting the younger population receiving refractive surgery
[21]. Men and women are equally affected. Right eyes are
more commonly infected than left eyes, because the right eye
is usually treated ﬁrst in a simultaneous bilateral procedure,
and thus receives more inocula. Ten percent of the post-
LASIK NTM keratitis patients have bilateral diseases [4,5].
Among the group of non-LASIK-related NTM keratitis, the
most common cause is ocular trauma. The mean age ranges
between 47 and 61 years. Men are predominantly affected
(up to 70%), owing to a higher prevalence of trauma in males
[2,3,22]. No bilateral cases of non-LASIK-related NTM
keratitis have been reported, and no laterality has been
observed [5].
Clinical features
Patients with NTM keratitis often have a history of trauma
with corneal foreign bodies or ocular surgery. The patients
usually complain of decreased vision, photophobia, and a
variable degree of pain [2,3]. The symptoms are caused by a
defect in the corneal epithelium, with inﬂammation of the
underlying corneal stroma caused by replicating organisms
[18]. The presentation of post-LASIK NTM keratitis is usually
more indolent than that of cases caused by trauma [5]. The
time interval between the onset of trauma and the appearance
of corneal infection ranges from days to weeks, whereas the
average time between LASIK and the onset of NTM keratitis is
3.4 weeks, and is up to 10–14 weeks in cases of keratitis
caused by SGM after LASIK [4].
The clinical manifestations of corneal lesions are variable.
The corneal inﬁltrates may be multifocal, or there may be a
single main lesion surrounded by many white, satellite lesions
[2,14,23]. Up to one-third of NTM keratitis cases may have no
epithelial defect at initial presentation [3]. This ﬁnding suggests
that the infectious process is slow, and that the corneal
epithelium can heal after the inﬁltrate extends to the corneal
stroma. This is contrast to the typical ﬁndings of epithelial
(a)
(b)
FIG.1. Characteristic patterns of non-tuberculous mycobacterial
keratitis. (a) Mycobacterium fortuitum keratitis showing paracentral
stromal inﬁltrates with radiating projections, mimicking a ‘cracked
windshield’ appearance. (b) Infectious crystalline keratopathy charac-
terized by white, crystalline, refractile, branching stromal inﬁltrates.
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defects in cases of infectious keratitis. The anterior chamber is
usually silent, but hypopyon can be present in inappropriately
treated cases [2]. In the early course of NTM keratitis, the
corneal inﬁltrates may have radiating projections, mimicking a
‘cracked windshield’ appearance, which is believed to be
characteristic and a useful sign of NTM keratitis (Fig. 1a) [23].
Infectious crystalline keratopathy, characterized by branching,
intrastromal opacity, and minimal inﬂammation, has also been
described in a few cases (Fig. 1b) [24].
All of the above ﬁndings can be observed in NTM keratitis
patients after either trauma or LASIK. In general, patients with
a history of minor corneal trauma, such as corneal abrasion or
that caused by a foreign body, may present with a superﬁcial
process and less inﬂammation; whereas patients with a history
of intraocular surgery, such as penetrating keratoplasty or
cataract extraction, tend to develop deeper and denser
inﬁltrates of the wound [2]. For post-LASIK patients, the
lesions appear to be entirely within the lamellar ﬂap or at the
ﬂap interface. Anterior extension of inﬁltrates with ﬂap
perforation or posterior extension into the stroma is less
frequent, and occurs in cases with delay treatment [4,5,21].
Diagnosis
The diagnosis of NTM keratitis is often delayed [2,3,5]. Earlier
studies have shown that the average duration from symptom
onset to diagnosis is 10 weeks (range: 1 week to 2 months)
[2,3]. However, as clinicians have gained more experience, the
duration has shortened. The clinical features of NTM keratitis
can mimic those of infectious keratitis from other causes,
especially fungus, herpes simplex virus, and Acanthamoeba
[5,7]. All of these cases may be associated with a history of
ocular trauma, and present with corneal inﬁltrates with an
intact epithelium, a waxing and waning course, and a poor
response to antibiotic treatment. The deﬁnite identiﬁcation of
the causative organism requires corneal scraping to obtain
materials for stains and cultures. For cases of keratitis after
LASIK, the ﬂap should be lifted, and cultures from the interface
should be performed [21].
Acid-fast stains, such as Ziehl–Neelsen stain, are commonly
used in modern laboratories [5,8]. It is important to mention
that an inadequate amount of specimen and the difﬁculty in
decolorizing non-tuberculous mycobacteria at 20% sulphuric
acid lower the accuracy of diagnosis. Acid-fast stain has a
sensitivity of only 22–78% as compared with culture [25].
Fluorescein-conjugated acid-fast stains can be helpful in
increasing the detection rate [26].
Although the exact sensitivities and speciﬁcities of the
culture techniques are not yet well established, the importance
of culturing the infected tissues cannot be overemphasized
[27]. Cultures amplify the scant amount of organisms available
in keratitis patients. In addition, cultures allow both pathogen
identiﬁcation and antibiotic susceptibility testing. All cultures
for suspected NTM cases should be performed on solid and
broth media. The advantages of solid media are numerous
[28]. They allow the observation of colony morphology and
growth rates, recognition of mixed infections, and quantiﬁca-
tion of the infecting organisms. The simultaneous use of
multiple culture media, including Löwenstein–Jensen medium,
blood agar, MacConkey agar, and Middlebrook 7H10 and
7H11 media, increases the growth of pathogens, and aids in the
identiﬁcation of speciﬁc non-tuberculous mycobacteria, par-
ticularly the slow growers [5,8,27].
Culture time may be relatively short (within 1 week) if
RGM are present, but the cultures should be kept for up to
8 weeks to ensure the growth of slow growers [5,8,27]. If an
inadequate quantity of specimen is collected, small amounts of
specimen can be mixed with sterile, balanced saline solution
and sent for culture in broth media, such as modiﬁed
Middlebrook 7H9 in conjunction with a ﬂuorescent mycobac-
terial growth indicator [5,8,27].
Categorizing the non-tuberculous mycobacteria to the
species level can provide correct characterization and infor-
mation for antibiotic selection [8]. Studies have shown that
molecular phenotyping of non-tuberculous mycobacteria with
PCR-based technology is more rapid and speciﬁc comparing to
traditional growth and biochemical tests [28]. For example,
PCR restriction fragment length polymorphism analysis has
been used to identify a case of M. szulgai keratitis [29]. In
addition, primers targeting the heat shock protein 65 (hsp65)
region of the mycobacterial genome have been used to identify
M. abscessus and M. fortuitum in patients with postoperative
endophthalmitis [30].
Medical Treatment
Medical treatment of NTM keratitis is often unsatisfactory,
because of delayed diagnosis, inadequate drug penetration,
and slow response to therapy. Resistance to most conven-
tional antibiotics and the emergence of resistant strains
during long-term treatment also contribute to poor thera-
peutic results [4,5,31]. As the antibiotic susceptibility of
NTM isolates varies among different species, an in vitro
susceptibility test of each individual strain is the cornerstone
for antimicrobial selection [5,8,27]. The broth microdilution
test is the reference technique for testing the antimicrobial
susceptibility of non-tuberculous mycobacteria [8]. However,
this method can be difﬁcult to perform for many laboratories
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in daily practice, owing to difﬁculties in microtitre plate
preparation and in reading the results. Other methods, such
as the disk diffusion assay [32] and the Etest assay [33],
have also been evaluated; however, the results are less
consistent than those obtained with the broth microdilution
method [8].
Aminoglycosides, macrolides and ﬂuoroquinolones are the
drugs that non-tuberculous mycobacteria are considered to be
sensitive to [5,23]. Earlier reports focusing on in vitro suscep-
tibilities have suggested that aminoglycosides, especially ami-
kacin, are the drugs of choice for NTM keratitis [34].
Furthermore, therapeutic levels of aminoglycosides can be
achieved by hourly application of fortiﬁed amikacin in rabbit
corneas [35]. However, its clinical result remains unsatisfac-
tory [2]. With single-agent therapy, it has been reported that
the failure rate can reach up to 60% in patients. In addition,
highly concentrated topical amikacin is poorly tolerated.
Conjunctival injection, chemosis and necrosis have been
observed clinically [36]. As a result, long-term use of topical
amikacin leads to poor compliance.
Macrolides, especially clarithromycin, have been shown to
have good in vitro sensitivity and favourable corneal penetra-
tion [37,38]. Although macrolides are considered to be
bacteriostatic, clarithromycin may provide a bactericidal effect
if used at a high concentration [37]. Even though the in vivo
efﬁcacy of clarithromycin against non-tuberculous mycobacte-
ria is not as good as the in vitro data would suggest [39],
treatment with topical clarithromycin or systemic clarithro-
mycin has been reported to be successful for NTM keratitis
[3,5]. However, toxic reactions and drug intolerance with
frequent topical clarithromycin application should also be
monitored [3].
Quinolones, such as ciproﬂoxacin, gatiﬂoxacin, and moxi-
ﬂoxacin, have all been reported to be effective topical agents
for NTM keratitis [40,41]. The in vitro susceptibility of non-
tuberculous mycobacteria to ﬂuoroquinolones varies from
resistant to sensitive among different studies [41,42]. An
animal study showed that ciproﬂoxacin had similar efﬁcacy to
amikacin and clarithromycin for M. chelonae keratitis [39].
Topical ciproﬂoxacin has been used to treat patients with
NTM keratitis who did not response to amikacin therapy.
However, the response rate with ciproﬂoxacin treatment is
only 44% [43]. Generally, ﬂuoroquinolones have better activity
against M. fortuitum than against M. chelonae–abscessus
[8,25,43]. The fourth-generation ﬂuoroquinolones, including
gatiﬂoxacin and moxiﬂoxacin, have a methyl group at C8. This
structural modiﬁcation contributes to their superior bacteri-
cidal activity and better ocular penetration than those obtained
with older generations of ﬂuoroquinolones [44]. As a result,
fourth-generation ﬂuoroquinolones have been reported to
give more favourable clinical outcomes, and are considered to
be alternative treatments for NTM keratitis [5,40].
NTM keratitis is clinically recalcitrant to treatment, and
requires long-term therapy to eradicate infection [3,5]. There
are no clear guidelines for the duration of therapy. The average
duration of treatment ranges from weeks to months [5].
Acquired resistance to amikacin, clarithromycin and ﬂuoroqu-
inolones restricts the use of these agents as monotherapy [45].
Although in vitro studies have demonstrated that amikacin
combined with a ﬂuoroquinolone or clarithromycin shows no
synergistic effect [32,46], combination therapy with two or
more antimicrobial agents is still recommended to decrease
the risk of the development of drug resistance [5]. Triple
therapy with amikacin (50 mg/L), topical clarithromycin
(10 mg/L) and fourth-generation ﬂuoroquinolones is suggested
for NTM keratitis [5]. Systemic antibiotics, such as clarithro-
mycin and doxycycline, may also be used for recalcitrant cases.
Another important concept in the management of NTM
keratitis is the avoidance of topical steroids. Corticosteroid
therapy may reduce the local host immune defence and
contribute to the development or progression of NTM
keratitis [3].
Surgical Treatment
The treatment of NTM keratitis requires not only appropri-
ate antibiotic therapy but also judicious surgical debridement
[2,5,31]. Progression or lack of response to topical therapy
should, in most cases, be followed by surgical interventions.
As most cases of NTM keratitis are localized to the
superﬁcial stroma, lamellar keratectomy is advocated for
the treatment of NTM keratitis. Lamellar keratectomy for
removal of the inﬁltrated corneal stroma offers several
beneﬁcial effects, lowering the bacterial load, facilitating
antibiotic penetration, removing the necrotic corneal stroma
to facilitate re-epithelialization, and providing sufﬁcient tissue
for culture and histopathological diagnosis [31]. In cases of
post-LASIK NTM keratitis, immediate ﬂap lifting, scraping and
irrigation of the stromal bed with fortiﬁed antibiotics are
recommended. Flap amputation is commonly performed in
recalcitrant and deeply seated infections [7,21]. Penetrating
keratoplasty or deep anterior lamellar keratoplasty is usually
reserved for intractable NTM keratitis [47]. All surgical
procedures have the risk of recurrence if adequate margins
are not obtained, requiring additional surgical procedures. In
advanced cases of NTM keratitis, the infection can progress
to the corneoscleral junction and lead to endophthalmitis.
Aggressive surgical debridement with pars plans vitrectomy,
intravitreal antibiotic injection or even enucleation may be
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necessary to eradicate the infection and to prevent systemic
involvement [18].
Outcomes
The prognosis for NTM keratitis remains unsatisfactory [5].
Earlier studies comparing the outcomes of different types of
infectious keratitis have shown that NTM keratitis has the
poorest response to medical treatment. Of patients suffering
from NTM keratitis, 68–85% require surgical intervention
[2,3,18]. The use of topical clarithromycin, amikacin and
newer-generation ﬂuoroquinolones has improved the general
outcomes in the last two decades [4,5,7]. Clinicians today have
a higher degree of suspicion regarding non-tuberculous
mycobacteria as a common cause of post-trauma or post-
LASIK keratitis. Therefore, we can recognize the infection
earlier and prompt rapid medical or surgical treatment.
According to the survey by Chang et al. in 2004 [21], 50% of
post-LASIK NTM keratitis patients were reported to have
moderate vision loss, whereas in a recent outbreak of post-
LASIK NTM keratitis that occurred between 2008 and 2009 in
Japan, only 17.9% of patients had ﬁnal visual acuity worse than
20/40 [48].
Conclusions
Non-tuberculous mycobacteria, especially the RGM, have been
continuing to emerge as important human pathogens that
cause infectious keratitis. These opportunistic pathogens can
form bioﬁlm and survive in artiﬁcial environments. Recom-
mendations for outbreak prevention include rigorous instru-
ment sterilization and the avoidance of possible contamination
of the surgical ﬁeld with tap water or distilled water. Clinicians
should have a high index of suspicion for recalcitrant inﬂam-
mation processes following trauma and LASIK. Adequate
sampling for laboratory tests is important for early diagnosis
and susceptibility testing. The avoidance of steroid treatment,
and the use of combination therapy with topical or systemic
amikacin, clarithromycin and ﬂuoroquinolones, are recom-
mended. Surgical intervention should be performed in cases
that do not show clinical improvement. Early recognition and
treatment are essential for improving the prognosis of this
devastating ocular infection.
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